Upload
biopartnering
View
595
Download
4
Tags:
Embed Size (px)
DESCRIPTION
This powerpoint gives you insights into the percentage of development/commercialization deals by highest phase at deal start (May 2012 - May 2014)
Citation preview
Business Forum PartneringDoing it right
Therapeutic Trends in Deals – BIO top 10
Deal phases
Source: Thomson Reuters Cortellis
PreClinical Phase 2 Phase 1 unspecified Phase 3 Launched Pre-registration Registered0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
50.0%
% of development/commercialization deals by highest phase at deal startMay 2012 - May 2014
Preclinical deals
Neopl
asm
Infe
ctio
us d
iseas
e
Neuro
logi
cal d
iseas
e
Gastro
inte
stin
al d
isea
se
Infla
mm
ator
y di
seas
e
Respi
rato
ry d
iseas
e
Imm
une
diso
rder
Metab
olic d
isor
der
Hemat
olog
ical d
isea
se
Endo
crin
e di
seas
e0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
% of pre-clinical development/commercialization deals by therapeutic areaMay 2012 - May 2014
Source: Thomson Reuters Cortellis
Phase 1 deals
Source: Thomson Reuters Cortellis
Neopl
asm
Neuro
logi
cal d
iseas
e
Infe
ctio
us d
iseas
e
Infla
mm
ator
y di
seas
e
Gastro
inte
stin
al d
isea
se
Cardi
ovas
cula
r dise
ase
Respi
rato
ry d
iseas
e
Imm
une
diso
rder
Muscu
losk
elet
al d
isea
se
Degen
erat
ion
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
% of phase 1 development/commercialization deals by therapeutic area May 2012 - May 2014
Phase 2 deals
Source: Thomson Reuters Cortellis
Neopl
asm
Gastro
inte
stin
al d
isea
se
Infe
ctio
us d
iseas
e
Infla
mm
ator
y di
seas
e
Neuro
logi
cal d
iseas
e
Imm
une
diso
rder
Derm
atol
ogica
l dise
ase
Respi
rato
ry d
iseas
e
Genito
urin
ary
dise
ase
Gynec
olog
y an
d ob
stet
rics
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
20.0%
% of phase 2 development/commercialization deals by therapeutic areaMay 2012 - May 2014
Phase 3 deals
Source: Thomson Reuters Cortellis
Gastro
inte
stin
al d
isea
se
Neopl
asm
Infe
ctio
us d
iseas
e
Hemat
olog
ical d
isea
se
Neuro
logi
cal d
iseas
e
Endo
crin
e di
seas
e
Cardi
ovas
cula
r dise
ase
Metab
olic d
isor
der
Infla
mm
ator
y di
seas
e
Respi
rato
ry d
iseas
e0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
% of phase 3 development/commercialization deals by therapeutic areaMay 2012 - May 2014
#BIO2014
convention.bio.org